References

1. Hughes ZA, Stanford SC. Increased noradrenaline efflux induced by local infusion of fluoxetine in the rat frontal cortex. Eur J Pharmacol 1996; 317:83-90.

2. Chen N-H, Reith MEA. Effects of locally applied cocaine, lidocaine and various uptake blockers in monoamine transmission in the ventral tegmental area of freely moving rats: A microdialysis study on monoamine interrelationships. J Neurochem 1994; 63:1701-1713.

3. Jordan S, Kramer GL, Zukas PK et al. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine and fluvoxamine. Synapse 1994; 18:294-297.

4. Perry KW, Fuller RW. Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats. J Neural Transm 1997; 104:953-966.

5. Matsumoto M, Yoshioka M, Togashi H et al. Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J Pharmacol Exp Ther 1995; 272:1044-1051.

6. Gobert A, Rivet J-M, Cistarelli L et al. a2-Adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 1997; 69:2616-2619.

7. Paez X, Liebowitz S. Changes in extracellular PVN monoamines and macronutrient intake after idazoxan or fluoxetine injection. Pharmacol Biochem Behav 1993; 46: 933-941.

8. Hajos-Korcsok E, Sharp T. Personal communication. 1998.

9. Benloucif S, Galloway MP. Facilitation of dopamine release in vivo by serotonin agonists: Studies with microdialysis. Eur J Pharmacol 1991; 200:1-8.

10. Chen N-H, Reith MEA. Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (± )-8-hydroxy-2-(di-n-propylamino)tetralin. J Neurochem 1995; 64:1585-1597.

11. Perry KW, Fuller RW. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 1992; 50:1683-1690.

12. Li X-M, Perry KW, Fuller RW. On the in vivo modulation of neostriatal dopamine release by fluoxetine and 5-hydroxy-L-tryptophan in conscious rats. J Pharm Pharmacol 1996; 48:825-828.

13. Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol 1995; 281:255-261.

14. Hughes ZA, Stanford SC. Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs. Br J Pharmacol 1998; 124:1141-1148.

15. Sammet S, Graefe K-H. Kinetic analysis of the interaction between noradrenaline and Na+ in neuronal uptake: Kinetic evidence for cotransport. Naunyn-Schmiedeberg's Arch Pharmacol 1979; 309:99-107.

16. Carlsson l, Abrahamson T. Characterization of the inhibitory effect of some antidepressant drugs on the outward transport of norepinephrine in the ischemic myocardium. J Pharmacol Exp Ther 1988; 247:715-720.

17. Langeloh A, Bonisch H, Trendelenburg U. The mechanism of the 3H-noradrenaline releasing effect of various substrates of uptake1: A multifactorial induction of outward transport. Naunyn-Schmiedeberg's Arch Pharmacol 1987; 336:602-610.

18. Povlock SL, Amara SG. The structure and function of norepinephrine, dopamine and serotonin transporters. In: Neurotransmitter Transporters, Structure, Function and Regulation. Reith MEA, ed. Totowa, New Jersey; Humana Press Inc., 1997:1-28.

19. Blakely RD, Ramamoorthy S, Qian Y et al. Regulation of antidepressant-sensitive serotonin receptors. In: Reith, MEA. ed. Neurotransmitter Transporters: Structure, Function and Regulation. Totowa, New Jersey: Humana Press Inc., 1997:29-72.

20. Rudnick G. Mechanisms of biogenic amine neurotransmitter transporters. In: Reith MEA, ed. Neurotransitter Transporters: Structure, Function and Regulation. Totowa, New Jersey: Humana Press Inc., 1997:73-100.

21. Ramamoorthy S, Bauman AL, Moore KR et al. Antidepressants- and cocaine-sensitive human serotonin receptor transporter: Molecular cloning, expression and chromosomal localization, Proc Natl Acad Sci USA 1993; 90:2542-2546.

22. Austin MC, Bradley CC, Mann JJ et al. Expression of serotonin transporter messenger RNA in the human brain. J Neurochem 1994; 62:2362-2367.

23. Barker El, Blakely RD. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Molec Pharmacol 1996; 50:957-965.

24. Sur C, Betz H, Schloss P. A single serine residue controls the cation dependence of substrate transport by the rat serotonin transporter. Proc Natl Acad Sci USA 1997; 94:7639-7644.

25. Rosenthal NE, Nazzanti CM, Barnett RL et al. Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. Mol Psychiatry 1998; 3:175-177.

26. Jayanthi LD, Prasad PD, Ramamoorthy S et al. Sodium and chloride-dependent cocaine-sensitive, high-affinity binding of nisoxetine to the human placental norepinephrine transporter. Biochemistry 1993; 32:12178-12185.

27. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 1991; 350:350-353.

28. Gu H, Wall SC, Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics and ion dependence. J Biol Chem 1994; 269; 7124-7130.

29. Pifl C, Hornykiewicz O, Giros B et al. Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human nora-drenaline and human dopamine transporter. J Pharmacol Exp Ther 1996; 277:1437-1443.

30. Giros, B, Mestikawt S, Godinot N et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Molec Pharmacol 1992; 42:383-390.

31. Tatsumi M, Groshan K, Blakely RD et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340:249-258.

32. Owens MJ, Morgan WN, Plott SJ et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283:1305-1322.

33. Pristupa ZB, Wilson JM, Hoffman BJ et al. Pharmacological heterogeneity of the cloned and native human dopamine transporter: Disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Molec Pharmacol 1994; 45:125-135.

34. Buck KJ, Amara SG. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Molec Pharmacol 1995; 46:1030-1037.

35. Erreboe I, Plenge P, Mellerup ET. Differences in brain 5-HT transporter dissociation rates among animal species. Pharmacol Toxicol 1995; 76:376-379.

36. Plenge P, Mellerup ET An affinity-modulating site on neuronal monoamine transport proteins. Pharmacol Toxicol 1997; 80:197-201.

37. Martel F, Azevedo I, Osswald W. Uptake of 3H-catecholamines by rat liver cells occurs mainly through a system which is distinct from uptake1 or uptake2. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 350:130-142.

38. Russ H, Staudt K, Martel F et al. The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur J Neurosci 1996; 8:1256-1264.

39. Paterson IA, Hertz L. Sodium-independent transport of noradrenaline in mouse and rat astrocytes in primary culture. J Neurosci Res 1989; 23:71-77.

40. Paczkowski NJ, Vuocolo HE, Bryan-Lluka LJ. Conclusive evidence for distinct transporters for 5-hydroxytryptamine and noradrenaline in pulmonary endothelial cells of the rat. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 353:423-430.

41. Michel M, Hiemke C, Ghraf R. Preferential uptake of norepinephrine into dopaminergic terminals of a synaptosomal preparation from rat cerebral cortex. Brain Res 1984; 301:149-152.

42. Wong DT, Bymaster FP, Horng JS et al. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenyl-propylamine. J Pharmacol Exp Ther 1975; 193:804-811.

43. Fleckenstein AE, Beyeler ML, Jackson JC et al. Methamphetamine-induced decrease in tryptophan hydroxylase activity: Role of 5-hydroxytryptaminergic transporters. Eur J Pharmacol 1997; 324:179-186.

44. Chen N-H, Reith MEA. Role of axonal and somatodendritic monoamine transporters in action of uptake blockers. In: Neurotransmitter Transporters, Structure, Function and Regulation. Reith MEA, ed. Totowa, New Jersey; Humana Press Inc., 1997:345-391.

45. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52:1023-1029.

46. Stanford SC Prozac: Panacea or puzzle? Trends Pharmacol Sci 1996; 17:150-154.

47. Wong DT, Horng JS, Bymaster FP. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci 1974; 15:471-479.

48. Cheng CHK, Costall B, Naylor RJ et al. The effect of 5-HT receptor ligands on the uptake of [3H]5-hydroxytryptamine into rat cortical synaptosomes. Eur J Pharmacol 1993; 239:211-214.

49. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984; 104:277-286.

50. Cheetham SC, Viggers JA, Slater NA et al. [3H] paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: Effect of administration of various antidepressant treatments. Neuropharmacology 1993; 32:737-743.

51. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 1987; 93:193-200.

52. Cool DR, Liebach FH, Ganapathy V. Interaction of fluoxetine with the human placental serotonin transporter. Biochem Pharmacol 1990; 40:2161-2167.

53. Harms HH. The antidepressant agents desipramine, fluoxetine, fluvoxamine and norzimelidine inhibit uptake of [3H]noradrenaline and [3H]5-hydroxytryptamine in slices of human and rat cortical brain tissue. Brain Res 1983; 275:99-104.

54. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996; 31:444-469.

55. Amsterdam JD, Fawcett J, Quitkin FMet al. Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study. Am J Psychiatry 1997; 154:963-969.

56. Caccia S, Fracasso C, Garattini S et al. Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology 1992; 31:343-347.

57. Dailey JW, Yan, QS, Mishra PKet al. Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. J Pharmacol Exp Ther 1992; 260:533-540.

58. Hyttel J, Over0 KF, Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology 1984; 83:20-27.

59. Engberg G. Citalopram and 8-OH-DPAT attenuate nicotine-induced excitation of central noradrenaline neurons. J Neural Transm 1992; 89:149-154.

60. Akaoka H, Aston-Jones G. Indirect, serotonergic agonists attenuate neuronal opiate withdrawal. Neurosci 1993; 54:561-565.

61. Brady LS. Stress, antidepressant drugs and the locus coeruleus. Brain Res Bull 1994; 35:545-556.

62. Curtis AL, Valentino RJ. Corticotropin-releasing factor neurotransmission in locus coeruleus: A possible site of antidepressant action. Brain Res Bull 1994; 35:581-587.

63. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994; 114:559-565.

64. Jenck F, Moreau J-L, Mutel V et al. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993; 231:223-229.

65. Narita N, Hashimoto K, Tomitaka S et al. Interactions of selective serotonin reuptake inhibitors with subtypes of o receptors in rat brain. Eur J Pharmacol 1996; 307:117-119.

66. Leonard BE. The potential contribution of sigma receptors in antidepressant actions. In: Skolnick P ed. Antidpressants: New Pharmacological Strategies. Totowa, New Jersey; Humana Press, 1997:159-172.

67. Mongeau R, De Montigny C, Blier P. Activation of 5-HT3 receptors enhances the electrically evoked release of [3H]noradrenaline in rat brain limbic structures. Eur J Pharmacol 1994; 256:269-279.

68. Suzuki M, Matsuda T, Asano S et al. Increase of noradrenaline release in the hypothalamus of freely-moving rat by postsynaptic 5-hydroxytrypamine1A receptor activation. Br J Pharmacol 1995; 115:703-711.

69. Blandina P, Goldfarb J, Walcott et al. Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther 1991; 256:341-347.

70. Goldfarb J, Walcott J, Blandina P. Serotonergic modulation of L-glutamic acid-evoked release of endogenous norepinephrine from rat hypothalamus. J Pharmacol Exp Ther 1993; 267:45-50.

71. Feuerstein TJ, Herrting G. Serotonin (5-HT) enhances hippocampal noradrenaline (NA) release: evidence for facilitatory 5-HT receptors within the CNS. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 333:191-197.

72. Kidd EJ, Laporte AM, Langlois K et al. 5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Res 1993; 612:289-298.

73. Allgaier C, Warnke P, Stangl AP et al. Effects of 5-HT receptor agonists on depolarization-induced [3H]-noradrenaline release in rabbit hippocampus and human neocortex. Br J Pharmacol 1995; 116:1769-1774.

74. Luppi PH, Aston-Jones G, Akaoka H et al. Afferent projections to the rat locus coeruleus demonstrated by retrograde and anterograde tracing with cholera-toxin B subunit and Phaseolus vulgaris leucoagglutinin. Neuroscience 1995; 65:119-160.

75. Vertes RP, Kocsis B. Projections of the dorsal raphe nucleus to the brainstem: PHA-L analysis in the rat. J Comp Neurol 1994; 340:11-26.

76. Aston-Jones G, Shipley MT, Chouvet G et al. Afferent regulation of locus coeruleus neurons: Anatomy, physiology and pharmacology. Prog Brain Res 1991; 88:47-75.

77. Renaud B, Buda M, Lewis BD et al. Effects of 5,6-dihydroxytryptamine on tyrosine hydroxylase activity in central catecholaminergic neurons of the rat. Biochem Pharmacol 1975; 24:1739-1742.

78. Haddjeri N, de Montigny C, Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxytryptamine system. Br J Pharmacol 1997; 120:865-875.

79. Reader TA, Briere R, Grondin L et al. Effects of p-chlorophenylalanine on cortical monoamines and on the activity of noradrenergic neurons. Neurochem Res 1986; 11:1025-1035.

80. Ferron A. Modified coeruleo-cortical noradrenergic neurotransmission after serotonin depletion by PCPA: electrophysiological studies in the rat. Synapse 1988; 2:532-536.

81. Shiekhattar R, Aston-Jones G. Sensory responsiveness of brain noradrenergic neurons is modulated by endogenous brain serotonin. Brain Res 1993; 623:72-76.

82. Aston-Jones G, Akaoka H, Chariety P et al. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J Neurosci 1991; 11:760-769.

83. Engberg G. A metabolite of buspirone increases locus coeruleus activity via a2-receptor blockade. J Neural Transm 1989; 91-98.

84. Gorea E, Davenne D, Lanfumey L et al. Regulation of noradrenergic coerulean neuronal firing mediated by 5-HT2 receptors: Involvement of the prepositus hypoglossal nucleus. Neuropharmacol 1991; 30:1309-1318.

85. Aston-Jones G, Shipley MT, Chouvet G et al. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 1991; 88:47-75.

86. Hamamura T, Lee Y, Fujiwara Y et al. Serotonin1A receptor agonists induce Fos protein expression in the locus coeruleus of the conscious rat. Brain Res 1997; 759:156-159.

87. Done CJG, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: Microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 1994; 33:411-421.

88. Hajos-Korcsok E, McQuade R, Sharp T. Influence of 5-HT1A receptors on central noradrenergic activity: Microdialysis studies using (±) MDL 73005EF and its enantiomers. Neuropharmacology 1999; 38:299-306.

89. Dalley JW, Mason K, Stanford SC. Increased levels of extracellular noradrenaline in the frontal cortex of rats exposed to naturalistic environmental stimuli: Modulation by acute systemic administration of diazepam or buspirone. Psychopharmacology 1996; 127:47-54.

90. Hajos-Korcsok E, Sharp T. 8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT1A and dopamine D1 receptors. Eur J Pharmacol 1996; 314:285-291.

91. Rasmussen K, Aghajanian GK. Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists. Brain Res 1986; 385:395-400.

92. Gorea E, Adrien J Serotonergic regulation of noradrenergic coerulean neurons: Electrophysiological evidence for the involvement of 5-HT2 receptors. Eur J Pharmacol 1988; 154:285-291.

93. Chiang C, Aston-Jones G. A 5-hydroxytryptamine2 agonist augments y-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neurosci 1993; 54:409-420.

94. Done CJG, Sharp T. Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. Br J Pharmacol 1992; 107:240-245.

95. Ennis C, Kemp JD, Cox B. Characterization of inhibitory 5-hydroxytrypamine receptors that modulate dopamine release in the striatum. J Neurochem 1981; 36:1515-1520.

96. Muramatsu M, Tamaki-Ohashi J, Usuki C et al. 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat striatal slices. Eur J Pharmacol 1988; 153:89-95.

97. Blandina P, Goldfarb J, Craddock-Royal B et al. Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum. J Pharmacol Exp Ther 1989; 251:803-809.

98. Yadid G, Pacak K, Kopin IJ et al. Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmaol Exp Ther 1994; 270:1158-1165.

99. Galloway MP, Suchowski CS, Keegan MJ et al. Local infusion of the selective 5-HT-1b agonist, CP-93,129 facilitates striatal dopamine release in vivo. Synapse 1993; 15:90-92.

100. Chen N-H, Reith MEA. [3H] Dopamine and [3H] serotonin release in vitro induced by electrical stimulation in A9 and A10 dopamine regions of rat brain: Characterization and responsiveness to cocaine. J Pharmacol Exp Ther 1993; 267:379-389

101. Jacocks HM, Cox BM. Serotonin-stimulated release of [3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: A comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. J Pharmacol Exp Ther 1992; 262:356-364..

102. Parsons LH, Justice JB. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res 1993; 606:195-199.

103. Yi S-J, Gifford AN, Johnson KM. Effect of cocaine and 5-HT3 receptor antagonists on 5-HT-induced [3H]dopamine release from rat striatal synaptosomes. Eur J Pharmacol 1991; 199:185-189.

104. Simon JR, Ghetti B. Is there a significant somatodendritic uptake of dopamine in the substantia nigra? Evidence from the weaver mutant mouse. Neurochem Int 1993; 22:471-477.

105. Carboni E. Tanda GL, Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 1990; 55:1067-1070.

106. Chen J, van Praag HM, Gardner EL. Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res 1991; 543:354-357.

107. Chen J, Paredes W, van Praag H et al. Presynaptic dopamine release is enhanced by 5-HT receptor activation in medial prefrontal cortex of freely moving rats. Synapse 1992; 10:264-266.

108. Benloucif S, Keegan MJ, Galloway MP Serotonin-facilitated dopamine release in vivo: Pharmacological characterization. J Pharmacol Exp Ther 1993; 265:373-377.

109. Bonhomme N, de Deurwaerdere P, Le Moal N et al. Evidence for 5-HT4 receptor involvement in the enhancement of striatal dopamine release induced by serotonin: A microdialysis study in the halothane-anesthetized rat. Neuropharmacology 1995; 34:269-279.

110. Steward LJ, Ge J, Stowe RL et al. Ability of 5-HT4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo. Br J Pharmacol 1996; 117:55-62.

111. Nurse B, Russell VA, Taljaard JJF. Characterization of the effects of serotonin on the release of [3H]dopamine from rat nucleus accumbens and striatal slices. Neurochem Res 1988; 13:403-407.

112. De Belleroche JS, Bradford HF. Presynaptic control of the synthesis and release of dopamine from striatal synaptosomes: A comparison between the effects of 5-hydroxytryptamine, acetylcholine and glutamate. J Neurochem 1980; 35:1227-1234.

113. De Deurwaerdere P, Bonhomme N, Lucas G et al. Serotonin enhances striatal dopamine outflow in vivo through dopamine uptake sites. J Neurochem 1996; 66:210-215.

114. Schmidt CJ, Black CK. The putative 5-HT3 agonist phenylbiguanide induces carrier-mediated release of [3H]dopamine. Eur J Pharmacol 1989; 167:309-310.

115. Prisco S, Pagannone S, Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: An electrophysiological study in vivo. J Pharmacol Exp Ther 1994; 271:83-90.

116. Yoshimoto K, McBride WJ. Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat. Neurochem Res 1992; 17:401-407.

117. Beasley CM, Masica DN, Potvin JH Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology 1992; 107:1-10.

118. Fozard JR, Mwaluko GMP. Mechanism of the indirect sympathomimetic effect of 5-hydroxytryptamine on the isolated heart of the rabbit. Br J Pharmacol 1976; 57:115-125.

Dealing With Drugs

Dealing With Drugs

Get All The Support And Guidance You Need To Be A Success At Dealing With Drugs. This Book Is One Of The Most Valuable Resources In The World When It Comes To A Parents Guide To The Drug Talk.

Get My Free Ebook


Post a comment